Abstract
Introduction: The incidence of type 1 diabetes (T1D) is increasing worldwide and there is a very large need for effective therapies. Essentially no therapies other than insulin are currently approved for the treatment of T1D. Drugs already in use for type 2 diabetes and many new drugs are under clinical development for T1D, including compounds with both established and new mechanisms of action.
Content of the Review: Most of the new compounds in clinical development are currently in Phase 1 and 2. Drug classes discussed in this review include new insulins, SGLT inhibitors, GLP-1 agonists, immunomodulatory drugs including autoantigens and anti-cytokines, agents that regenerate β-cells and others. Regulatory Considerations: In addition, considerations are provided with regard to the regulatory environment for the clinical development of drugs for T1D, with a focus on the United States Food and Drug Administration and the European Medicines Agency. Future opportunities, such as combination treatments of immunomodulatory and beta-cell regenerating therapies, are also discussed.Keywords: Type 1 diabetes, new drug development, regulatory environment, FDA, EMA, new mechanisms of action, insulins; anti-inflammatory drugs, immunomodulatory, islet regeneration.
Call for Papers in Thematic Issues
Advancing Diabetic Wound Healing: Mechanisms and Interventions
In recent years, diabetic wounds have become a global health concern with an increase in the incidence of diabetes. Diabetic wounds are a kind of chronic and refractory ulcer. It is generally due to microcirculatory disturbances and reduced levels of endogenous growth factors. Delayed cutaneous wound healing is a chronic ...read more
Advancing Insights into Type 1 Diabetes: From Mechanisms to Management
Type 1 diabetes (T1D) represents a significant global health challenge, requiring a deep understanding of its complex pathophysiology and the development of innovative strategies for prevention, treatment, and management. This thematic issue highlights the latest progress in understanding the autoimmune processes underlying T1D, advances in beta-cell biology, and novel therapeutic ...read more
Exerscience: Management of Diabetes by Physical Activity/Exercise
Physical activity/exercise is key to the management of diabetes and its complications. Studies have suggested that increased physical activity or regular exercise is associated with reduced risks of diabetes and its complications. However, challenges remained on how to promote physical activity or exercise efficiently, e.g., increase the adherence to physical ...read more
Next-Generation Drug Delivery Systems for Diabetes: Nanoparticles, Hydrogels, and Phytosome Technologies
This thematic issue, titled "Next-Generation Drug Delivery Systems for Diabetes: Nanoparticles, Hydrogels, and Phytosome Technologies," will focus on advanced formulation science to enhance diabetes treatment. It covers innovative platforms such as nanoparticles, responsive hydrogels, and phytosome technologies for improving the bioavailability, stability, and precision in delivering antidiabetic agents. Key areas ...read more
Related Journals
Anti-Cancer Agents in Medicinal Chemistry
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Current Bioactive Compounds
Current Cancer Drug Targets
Combinatorial Chemistry & High Throughput Screening
Current Cancer Therapy Reviews
Current Drug Safety
Current Drug Targets
Current Drug Therapy
Current Drug Metabolism
Related Books
Handbook of Poultry Parasites
Mucosal Vaccine Delivery Systems: The Future of Immunization (Part 2)
Mental Health, General Pediatrics, and Family Medicine
Pharmacology and Therapeutics, Parasitology and Internal Medicine
Obstetrics and Gynecology
Herbal Nanotherapy for Diabetes
The Impact of Pharma Technology on Cosmetics: Advancements and Innovations
Occupational Therapy Practice in Mental Health: Models, Conditions, Interventions, and Recovery
Advances in the Medicinal Chemistry of Neglected Tropical Disease and Related Infectious Diseases
Research Protocols for Ophthalmic Disease Mechanisms and Therapeutics: Glaucoma - Ocular Hypertension
120
9